Pfizer
PFE Big PharmaGlobal pharmaceutical leader with blockbuster franchises in vaccines (Prevnar, Comirnaty), cardiovascular (Eliquis), and oncology. Known for rapid COVID-19 vaccine development and strategic acquisitions including Seagen.
FDA Novel Drug Designations
(2017-2024)See 14 novel approvals →
Pfizer at a Glance
- Leading 42 drug targets across portfolio
- Fast trial execution (11 months median completion)
Pfizer's Key Drugs
Pfizer's core commercial portfolio centers on IBRANCE, XELJANZ, XELJANZ XR, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy
Moderately to severely active rheumatoid arthritis
Rheumatoid Arthritis
Hemophilia A
Vasomotor Symptoms
Pfizer's Recent FDA Approvals
Pfizer secured 9 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Pfizer's Therapeutic Areas
Pfizer's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 12 biologic and 84 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Pfizer's Top Competitors
Pfizer's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Eli Lilly, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Pfizer Pipeline Snapshot
Pfizer has 867 active clinical programs from ClinicalTrials.gov — 240 Phase 3, 267 Phase 2 and 360 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 257/390 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (23)
Discontinued (3)
Company Info
- First Approval
- 1942-05-08
- Latest
- 2026-06-24
- Applications
- 870
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges